Obesity therapies in development include retatrutide (triple agonist), CagriSema (GLP-1/amylin), survodutide (GLP-1/glucagon), orforglipron (oral GLP-1), the amylin analogues cagrilintide and petrelintide, next-generation GIP agents and muscle-preserving drugs such as bimagrumab. All of these remain investigational. Oral semaglutide 25 mg has already graduated to approval.
Graduated to approved
Oral semaglutide 25 mg is a high-dose oral formulation of semaglutide for chronic weight management: a GLP-1 receptor agonist, taken as an oral peptide with specific food and water dosing conditions. It is 🟢 Established — FDA-approved (December 2025), the first oral GLP-1 for obesity, and it has therefore left this database; its details sit on its own drug page. It is also the benchmark the agents below are working toward. → Semaglutide (/treat/glp1/semaglutide)
The emerging agents
| Agent | Mechanism | Phase and regulatory status | Human evidence | Risks and unknowns | Potential clinical role |
|---|---|---|---|---|---|
| 1. Retatrutide 🟠 Limited |
GLP-1 / GIP / glucagon triple agonist — adds a glucagon arm (possible ↑ energy expenditure) to incretin appetite effects | Phase 3 (TRIUMPH program) — not FDA-approved | Phase 3 TRIUMPH-1: up to ~30.3% mean total weight loss at the highest dose (topline); a trial average, not a personal result | Glucagon effects on glucose, heart rate and the liver; GI tolerability; long-term safety of triple agonism. Durability, muscle and body-composition effects, cardiovascular outcomes and real-world tolerability all open | Largest incretin-era weight loss reported to date, with possible added liver and metabolic benefit from glucagon agonism. If approved, a high-efficacy option beyond dual agonists, pending safety confirmation |
| 2. CagriSema 🟠 Limited |
Cagrilintide (long-acting amylin analogue) + semaglutide (GLP-1) — complementary appetite pathways | Phase 3 (REDEFINE program) — not FDA-approved | REDEFINE 1: ~22.7% mean total weight loss. REDEFINE 4: ~23%, but missed non-inferiority versus tirzepatide in the head-to-head | GI tolerability; the added complexity and cost of a combination; whether adding amylin truly beats the best single dual agonist, which REDEFINE 4 does not support; durability and muscle effects | High efficacy, and it validates amylin as a partner mechanism, with possible favourable body composition that remains unproven. A strong option if approved, though not an automatic upgrade over tirzepatide on current data |
| 3. Survodutide 🔴 Experimental |
GLP-1 / glucagon dual agonist — the glucagon arm is of particular interest for the liver | Investigational — not approved for obesity or MASH | Reported improvement in MASH endpoints in earlier-phase work, stated qualitatively. → GLP-1 & Fatty Liver | Glucagon effects on glucose and heart rate; GI tolerability; weight efficacy versus approved drugs and confirmatory MASH and safety data still outstanding | Treats obesity and MASH together through a distinct mechanism; a possible future option where that combination is the driver, if trials confirm |
| 4. Orforglipron 🟠 Limited |
Non-peptide, small-molecule oral GLP-1 agonist, without the strict peptide food and water dosing rules | Phase 3 data reported — investigational, not approved | Phase 3 results in obesity and in diabetes, with efficacy stated qualitatively | GI tolerability; long-term safety still being defined; efficacy relative to injectable incretins, durability and approval timing unknown | A scalable oral option that could widen access beyond injectables and, if approved, serve as an oral first-line choice, distinct from oral semaglutide because that drug is a peptide |
| 5. Cagrilintide 🔴 Experimental (standalone) |
Amylin receptor agonist — appetite suppression through a non-incretin pathway | Investigational as monotherapy — not approved | The most mature evidence sits within CagriSema (entry 2); standalone data are earlier and qualitative | GI tolerability; standalone efficacy uncertain against incretins; whether amylin preserves lean mass is a hypothesis rather than a finding | A different mechanism and side-effect profile, most plausibly a combination partner rather than a standalone drug |
| 6. Petrelintide 🔴 Experimental |
Amylin receptor agonist (non-incretin appetite pathway) | Early clinical — investigational, not approved | Early-phase data, with efficacy and profile still being defined | Long-term safety unknown; GI effects; standalone efficacy and comparison with incretins and with cagrilintide all open | Possibly a cleaner-tolerability or lean-mass-sparing amylin option, unproven as yet, as monotherapy or in combination |
| 7. Next-generation GIP agents 🔴 Experimental |
GIP-directed. Both GIP agonism and, paradoxically, antagonism show metabolic effects, so the biology is genuinely unsettled | Preclinical to early clinical — investigational | Limited standalone human data; most GIP evidence to date comes bundled inside tirzepatide. → Tirzepatide | Risks uncertain, because the mechanism itself is not resolved; whether agonism or antagonism is the better strategy, and whether there is standalone value, both open | Fine-tuning of the GIP arm for efficacy, tolerability or body composition. A direction rather than a named product, most useful as a combination component |
| 8. Bimagrumab / activin-pathway agents 🔴 Experimental |
Activin/myostatin-pathway blockade, intended to shift loss toward fat and protect fat-free mass | Investigational — not approved for this use | Early data suggest more fat loss with relatively more lean-mass preservation, stated qualitatively | Long-term safety unknown; other activin-pathway effects; and whether measured lean mass preserved means real strength and function preserved, which is not the same thing | Keeps loss closer to fat-specific and protects function, particularly in older or frailer patients. A future add-on to incretin therapy, unproven as yet. → GLP-1 & Muscle Loss |
| 9. Precision obesity / pharmacogenomics 🔴 Experimental (common obesity) / 🟢 Established (rare monogenic, via setmelanotide) |
Biomarker- or genotype-guided treatment selection, matching the drug to the person; not a drug itself | 🔴 Experimental for common obesity; established only in rare monogenic disease | Heritability ~40–70%; setmelanotide works for defined monogenic obesity (POMC, LEPR, Bardet-Biedl). No validated drug-response test exists for common obesity. → Genetics of Obesity | Premature commercial obesity gene tests; equity and access; over-claiming; and whether polygenic scores add real predictive value in practice | Companion tests guiding first-line choice, with less trial and error. A long-term direction; today only monogenic targeting is clinical |
What the evidence says: the emerging pipeline
- What we know: one agent has crossed into approval, oral semaglutide 25 mg. The rest are investigational, with the strongest late-stage efficacy signals from retatrutide and CagriSema.
- What we think: in our view triple agonism and amylin combinations will lift efficacy, oral small molecules will widen access, and muscle-preservation and precision approaches will shape the quality of treatment rather than the size of the weight loss.
- What we don't know: long-term safety and outcomes; whether combinations reliably beat the best single agent, which REDEFINE 4 cautions against assuming; and whether precision matching works for common obesity.
- What follows clinically: treatment decisions today rest on approved options, and each agent above is read through its phase badge and regulatory status rather than its headline percentage.
Which approved treatment fits a particular person, and whether a trial of an investigational agent is worth discussing, is a question for individual assessment at the practice.
Questions patients ask
Which obesity drugs are in development?
Retatrutide, CagriSema, survodutide, orforglipron, the amylin analogues cagrilintide and petrelintide, next-generation GIP agents and muscle-preserving drugs — all investigational. Oral semaglutide 25 mg is already approved. Grade 🟠 Limited (pipeline) → The Next Generation of Obesity Medicine
Which emerging drug produces the most weight loss?
Retatrutide has reported the highest figure, up to ~30.3% mean in phase 3. It is investigational, and a trial average is not a personal result. Grade 🟠 Limited
Is CagriSema better than the drugs available now?
Not clearly. It reached ~22.7% in REDEFINE 1 but missed non-inferiority versus tirzepatide in REDEFINE 4, so a newer combination did not beat the best approved dual agonist. Grade 🟠 Limited
What is the difference between orforglipron and oral semaglutide?
Oral semaglutide is an approved oral peptide with strict food and water dosing rules. Orforglipron is an investigational non-peptide small molecule, which may be simpler to take. Grade A 🟢 (semaglutide) / 🟠 (orforglipron) → Semaglutide
Are amylin drugs safer for muscle?
That is a hypothesis rather than an established fact. Amylin agents and activin-pathway drugs such as bimagrumab are being studied for body composition, but lean mass on a scan is not the same as strength. Grade 🔴 Experimental → GLP-1 & Muscle Loss
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: TRIUMPH (retatrutide); REDEFINE 1/4 (CagriSema); FDA approval of oral semaglutide 25 mg (Dec 2025); survodutide, orforglipron, cagrilintide, petrelintide, bimagrumab and next-gen GIP development programs; setmelanotide labeling. All investigational agents re-verified on update. Educational only; pipeline agents are not available treatments and this is not individualized advice.
